Dr. Robert A. Franklin, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 118
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OH license 35.133276 -
Hospitalist Physician
OH license 35.133276 -
Internal Medicine Physician
OH license 35.133276
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Cincinnati Medical Center, LLC Cincinnati, OH
- West Chester Hospital West Chester, OH
Medical groups
- University of Cincinnati Physicians Company LLC (1,506 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 118
- Services billed
- 348
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 207 | 51 |
| Established patient office or other outpatient visit, 30-39 minutes | 48 | 37 |
| New patient office or other outpatient visit, 60-74 minutes | 19 | 19 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 17 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Abiraterone Acetate | 60 |
| Prednisone Other prescribers in Cincinnati, OH | 39 |
| Xtandi (enzalutamide) | 23 |
| Welireg (belzutifan) | 17 |
| Prochlorperazine Maleate Other prescribers in Cincinnati, OH | 16 |
| Nubeqa (darolutamide) | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 7 payments worth $293 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $151 |
|---|---|
| GE Healthcare | $51.66 |
| Progenics Pharmaceuticals, Inc. | $29.60 |
| Taiho Oncology, Inc. | $23.63 |
| Gilead Sciences, Inc. | $21.99 |
| E.r. Squibb & Sons, L.l.c. | $15.20 |
| Food and Beverage | $293 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $90,569 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer
Janssen Research & Development, LLC - A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Ca…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.